Bone health in breast cancer survivors

Journal of Cancer Research and Therapeutics

Volumn 7, Issue 3, 2011, Pages 256-263

  Abdel Razeq, Hikmat ^a   Awidi, Abdulla ^b  

^a KING HUSSEIN CANCER CENTER   (Jordan)

^b JORDAN HOSPITAL   (Jordan)

Author keywords

Bisphosphonates; bone health; breast cancer; denosumab; osteopenia; osteoporosis

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOPHOSPHAMIDE; DENOSUMAB; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; LEUPRORELIN; METHOTREXATE; PROGESTERONE RECEPTOR; RISEDRONIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BACKACHE; BONE DENSITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVOR; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN DEFICIENCY; FATIGUE; FRACTURE; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MEDLINE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SIDE EFFECT; SUPPLEMENTATION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; UTERUS TUMOR; VITAMIN D DEFICIENCY;

ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS; SURVIVORS; TREATMENT OUTCOME;

EID: 81855228706     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.87006     Document Type: Review

References (68)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009;59:225-49.
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92. (Pubitemid 41549890)
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365:1687-717.
4. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83. (Pubitemid 46594124)
5. Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 2006;42:895-904. (Pubitemid 44294521)
6. LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, et al. Use of luteinising-hormone- releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23.
7. Raisz LG. Estrogen and bone: New pieces to the puzzle. Nat Med 1996;2:1077-8. (Pubitemid 26338622)
8. Pacifici R. Estrogen cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11:1043-51. (Pubitemid 26321353)
9. Eriksen RF, Langdahl B, Vesterby A, Rungby J, Kassem M. Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women. J Bone Miner Res 1999;14:1217-21. (Pubitemid 29314067)
10. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005;208:154-68. (Pubitemid 41746391)
11. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 2006;116:1186-94.
12. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10. (Pubitemid 37310221)
13. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57. (Pubitemid 43016814)
14. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-96.
15. Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD. Tamoxifen use and osteoporotic fracture risk: A population-based analysis. J Clin Oncol 2008;26:5227-32.
16. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84. (Pubitemid 26022463)
17. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006;24:675-80. (Pubitemid 46630433)
18. Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J Steroid Biochem Mol Biol 2005;95:75-81. (Pubitemid 41148977)
19. Simpson ER, Dowsett M. Aromatase and its inhibitors: Significance for breast cancer therapy. Recent Prog Horm Res 2002;57:317-38.
20. Goss PE, Qi S, Josse, RG Pritzker KP, Mendes M, Hu H, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004;34:384-92. (Pubitemid 38314903)
21. Goss PE, Ingle JN, Chapman JA, Ellis MJ, Sledge GW, Budd GT, et al. Final analysis of NCIC CTG MA.27: A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. Program and abstracts of the 33rd Annual San Antonio Breast Cancer Symposium; Dec 8-12, 2010; San Antonio, Texas. Abstract S1-1.
22. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole Tamoxifen Alone or in Combination Trial 18233230. J Clin Oncol 2008;26:1051-7.
23. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 year's adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
24. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
25. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007;8:119-27. (Pubitemid 46158372)
26. Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010;124:153-61.
27. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629-35. (Pubitemid 46630537)
28. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71. (Pubitemid 41535367)
29. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
30. Siris ES, Leventhal BG, Vaitukaitis JL. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med 1976;294:1143-6.
31. Bakri YN, Pedersen P, Nassar M. Normal pregnancy after curative multiagent chemotherapy for choriocarcinoma with brain metastases. Acta Obstet Gynecol Scand 1991;70:611-3.
32. Warne GT, Failey KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973;289:1159-62.
33. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29. (Pubitemid 26134232)
34. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-8. (Pubitemid 350002882)
35. National Osteoporosis Foundation: Fast Facts on Osteoporosis. Available from: http://www.nof.org/osteoporosis/diseasefacts.htm Last accessed 2010 Dec 15.
36. Camacho PM, Dayal AS, Diaz JL, Nabhan FA, Agarwal M, Norton JG, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol 2008;26:5380-5.
37. Syed Z, Khan A. Bone densitometry: Applications and limitations. J Obstet Gynaecol Can 2002;24:476-84.
38. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: Scientific review. JAMA 2002;288:1889-97. (Pubitemid 35168145)
39. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3 rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008;42:467-75.
40. Faulkner KG. Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 2000;15:183-7. (Pubitemid 30095704)
41. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9. (Pubitemid 26147662)
42. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73.
43. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev 2008;34 Suppl 1:S3-18.
44. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer: A consensus paper of the Belgian Bone Club. Osteoporos Int 2007;18:1439-50. (Pubitemid 47512686)
45. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57. (Pubitemid 46606220)
46. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 2003;21:1447-51. (Pubitemid 46594094)
47. Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: Changes from 1998 to 2002. J Clin Oncol 2009;27:1054-61.
48. Lester JE, Dodwell D, Horsman JM, Mori S, Coleman RE. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 2006;94:30-5. (Pubitemid 43088537)
49. Schwartz AL, Winters-Stone K, Gallucci B. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 2007;34:627-33.
50. Demark-Wahnefried W, Pinto BM, Gritz ER. Promoting health and physical function among cancer survivors: Potential for prevention and questions that remain. J Clin Oncol 2006;24:5125-31. (Pubitemid 46623198)
51. Khan AA, Brown JP, Kendler DL, Leslie WD, Lentle BC, Lewiecki EM, et al. The 2002 Canadian bone densitometry recommendations: Take-home messages. CMAJ 2002;167:1141-5. (Pubitemid 35365299)
52. Good PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D Leveis in early breast cancer. J Clin Oncol 2009;27:3757-63.
53. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.
54. Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. Gynecol Oncol 2010;117:139-45.
55. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008;112:1001-10. (Pubitemid 351304583)
56. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21:2188-94.
57. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-36. (Pubitemid 350002883)
58. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85.
59. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840-9.
60. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 2010;28:967-75.
61. Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, et al. Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008;26:2644-52.
62. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008;14:6336-42.
63. Park-Wyllie L, Mamdani M, Juurlink D, Hawker G, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305:783-9.
64. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Poestlberger S, Dubsky PC, et al. Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 2010;28:15s, (abstr 533).
65. Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04). Program and abstracts of the 33rd Annual San Antonio Breast Cancer Symposium; Dec 8-12, 2010; San Antonio, Texas. Abstract S4-5.
66. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5. (Pubitemid 38988958)
67. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006;6:1041-50. (Pubitemid 44497128)
68. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-82.